To Explore The Prediction Effect Of CD39+CD8+T Cell Ratio In Peripheral Blood Of Non-small Cell Lung Cancer Patients Using PD-1 Inhibitors

Objective:Previous studies have shown that some non-small cell lung cancer patients could benefit from immune checkpoint inhibitors,but the response rate in the general population is only about 20%.Therefore,before immunotherapy,it is of great significance in clinical field to explore the indicators to predict the efficacy of immunotherapy and to find the beneficiaries as much as possible.This study aimed to explore whether peripheral blood CD39+CD8+T cell ratio could be an effective biomarker using PD-1 inhibitors in non-small cell lung cancer.Methods:This study prospectively enrolled patients with NSCLC who received PD-1inhibitor at the First Affiliated Hospital of Nanchang University from June 2021 to November 2021.Flow cytometry was used to detect the proportion of peripheral blood CD8+T cells and CD39+CD8+T cells before immunotherapy,3 weeks and 6weeks after immunotherapy respectively.The levels of IL-2,TNF-α and IFN-γcytokines in peripheral blood were analyzed by ELISA.The cut-off value was determined by ROC curve,and the difference between the groups was compared by non-parametric test.Results:Before immunotherapy,the proportion of CD39+CD8+T cells in peripheral blood of patients with NSCLC can predict the efficacy of PD-1 inhibitors.W hen the cut-off value exceeds 3.125%,the ORR was 83.3%,while when the c ut-off value is lower than 3.125%,the ORR was 7.7%.In response,The prop ortion of CD39+CD8+T cells increased at 6 weeks after immunotherapy compa red with 3 weeks after immunotherapy(9.35%VS5.67%,P=0.028);The proporti on of CD39+CD8+T cells increased at 6 weeks after immunotherapy compared with that before treatment(9.35%vs4.87%,P=0.025).In non-responders,There was no significant difference in the proportion of CD39+CD8+T cells.During immunotherapy,the changes of il-2,TNF-α and IFN-γ in peripheral blood we re not statistically significant.Conclusion:For non-small cell lung cancer patients using PD-1 inhibitors,the higher the proportion of CD39+CD8+T cells in peripheral blood before immunotherapy,the higher the ORR rate,which may be an effective biomarker to predict the efficacy of PD-1 inhibitors.